

**Purified anti-human CD81 (TAPA-1)**

**Catalog # / Size:** 2347505 / 25 µg  
2347510 / 100 µg

**Clone:** 5A6

**Isotype:** Mouse IgG1, κ


**Immunogen:** Human OCI-LY8 cell line

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

**Concentration:** 0.5



Human peripheral blood lymphocytes stained with purified CD81 (5A6) conjugated with PE

**Applications:**

**Applications:** Other

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** Additional reported applications (for the relevant formats) include: Western Blotting<sup>3</sup> and immunoprecipitation<sup>2,3</sup>.

**Application References:**

1. Menno C, *et al.* 2010. *J. Clin. Invest.* 4:1265.
2. Oren R, *et al.* 1990. *Mol. Cell. Biol.* 8:4007. (IP)
3. Clark K, *et al.* 2004. *J. Biol. Chem.* 279(19):19401. (IP, WB)
4. Mochida K, *et al.* 2008. *J. Virol.* 13:6711.
5. Rappa G, *et al.* 2014. *Mol Cancer Res.* 12:1840. [PubMed](#)

**Description:** CD81 is a 26 kD non-glycosylated member of the tetraspanin superfamily (TM4SF), also known as TAPA-1 (target of an antiproliferative antibody). CD81 is expressed on T and B cells, NK cells, monocytes, dendritic cells, thymocytes, endothelial cells, and fibroblasts. It also has low levels of expression on granulocytes. CD81 induces B cell adhesion via VLA-4 integrin and has been shown to play a role in early T cell development. CD81 associates with several other cell-surface proteins in a multimolecular complex, including CD19, CD21, CD20, CD37, CD53, and CD82 in B cells, and CD4, CD8, and CD82 in T cells.

**Antigen References:**

1. Menno C, *et al.* 2010. *J. Clin. Invest.* 4:1265.
2. Fearon D, *et al.* 1995. *Annu. Rev. Immunol.* 13:127.
3. Wright M, *et al.* 1994. *Immunol. Today* 15:588.